Vascular smooth muscle cell phenotypic switching and remodeling machinery (VSMC phenotypic switching)

Vascular smooth muscle cell (VSMC) phenotypic switching and remodeling machinery refers to the coordinated molecular processes that allow VSMCs to transition between a differentiated contractile state and a dedifferentiated synthetic state (PMID: 26106113). In healthy arteries, VSMCs exhibit a contractile phenotype characterized by high expression of proteins like alpha-smooth muscle actin (ACTA2) and smooth muscle myosin heavy chain (MYH11), which are essential for maintaining vascular tone (PMID: 15105460). In response to vascular injury or environmental cues such as inflammation and growth factors like PDGF-BB, VSMCs undergo phenotypic switching to a synthetic state, increasing their capacity for proliferation, migration, and extracellular matrix synthesis (PMID: 30124471). This remodeling machinery is regulated by a network of transcription factors, including the Serum Response Factor (SRF)/Myocardin complex which promotes the contractile state, and Kruppel-like factor 4 (KLF4) which suppresses it (PMID: 15105460). Dysregulation of this process is a hallmark of cardiovascular diseases such as atherosclerosis, hypertension, and neointimal hyperplasia following clinical interventions like stenting (PMID: 26106113). Pharmacological targeting of this machinery often involves the use of anti-proliferative agents like Sirolimus (mTOR inhibitor) or Paclitaxel (microtubule stabilizer) in drug-eluting stents to prevent excessive remodeling and restenosis (PMID: 24651634).

Other names

VSMC phenotypic modulationVSMC plasticityVascular remodeling machinerySmooth muscle cell dedifferentiation

Inhibition of mTOR signaling, stabilization of microtubules, and modulation of transcription factor activity to suppress the synthetic phenotype and promote or maintain the contractile state.